A5053554017- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Virus-based gene therapy research
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Gallbladder and Bile Duct Disorders
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Liver Disease Diagnosis and Treatment
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Surgical Simulation and Training
- Diversity and Career in Medicine
- Viral Infectious Diseases and Gene Expression in Insects
- Intraperitoneal and Appendiceal Malignancies
- Gastrointestinal Tumor Research and Treatment
- Liver Disease and Transplantation
- Economic and Financial Impacts of Cancer
- Viral gastroenteritis research and epidemiology
Mayo Clinic in Arizona
2021-2025
Mayo Clinic
2022-2025
WinnMed
2022-2025
University of Michigan
2014-2025
Twitter (United States)
2024
City Of Hope National Medical Center
2016-2023
City of Hope
2016-2023
Mayo Clinic in Florida
2023
Broward Health Medical Center
2023
Pancreas Centre (Canada)
2022
Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly predicts response, and biochemical (CA 19-9) markers are not useful (nonsecretors/nonelevated) many patients. Pathologic response highly survival post-NAT, but only known postoperatively. Because metabolic (FDG-PET) reveals primary tumor viability, this study aimed to evaluate our experience with preoperative FDG-PET...
Background: Accurate staging prior to resection of pancreatic ductal adenocarcinoma (PDAC) is imperative avoid unnecessary operative morbidity and oncologic futility in patients with occult intraabdominal distant metastases. We aimed determine the diagnostic yield laparoscopy (SL) identify factors associated increased risk positive (PL) modern era. Study Design: Patients radiographically localized PDAC who underwent SL 2017-2021 were retrospectively reviewed. The was defined as proportion...
Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect patients undergoing liver resection for a cancer-related indication remains unclear.
In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic benefit of surgery and perioperative outcomes for large multifocal tumors or contiguous organ involvement remain to be defined.To develop externally validate a simplified prognostic score ICC determine ICCs involvement.This study contemporary cohort merged data from California Cancer Registry (January 1, 2004, through December 31, 2011) Office Statewide Health Planning Development inpatient database. Clinicopathologic...
Abstract Background Selected studies have reported improved outcomes in laparoscopic compared with open distal pancreatic resection. Concerns regarding failure to achieve proper oncological resection and compromised long-term remain. This study investigated whether postoperative survival after pancreatectomy are comparable those an procedure. Methods retrospective case–control included patients who underwent for resectable adenocarcinoma between 2010 2013, identified from the National Cancer...
Distant metastases are the strongest predictor of poor prognosis for patients with neuroendocrine tumors (NETs). Cytoreductive hepatectomy (CRH) can relieve symptoms hormonal excess and prolong survival liver (NETLMs), but long-term outcomes poorly characterized.This retrospective single-institution analysis analyzed who underwent CRH well-differentiated NETLMs from 2000 to 2020. Kaplan-Meier estimated symptom-free interval overall progression-free survival. Multivariable Cox regression...
Abstract Background The management of invasive intraductal papillary mucinous cystic neoplasm (I-IPMN) does not differ from de novo pancreatic ductal adenocarcinoma (PDAC); however, I-IPMNs are debated to have better prognosis. Despite being managed similarly PDAC, no data available on the response I-IPMN neoadjuvant chemotherapy. Methods All patients undergoing resection for a 2011 2022 were included. PDAC and cohorts compared evaluate therapy (NAT) overall survival (OS). Results This study...
How the oncologic outcomes after robotic distal pancreatectomy (RDP) compare to those laparoscopic (LDP) remains unknown.Using National Cancer Database (NCDB), we analyzed all patients undergoing LDP or RDP for resectable pancreatic adenocarcinoma over a 4-year period (2010-2013).Of 704 eligible patients, 605 (86%) underwent and 99 (14%) RDP. The median follow-up was 25 months. There were no differences in two groups with respect sociodemographic, clinicopathologic, treatment...
Primary liver sarcomas (PLS) are rare. Published series limited by small numbers of patients.We reviewed the National Cancer Database (2004-2014) for patients who underwent surgical resection PLS.Of 237 identified, majority were female (60.8%), with median age 52 years. Histologies were: epithelioid hemangioendothelioma (n = 67), angiosarcoma 64), leiomyosarcoma 33), embryonal rhabdomyosarcoma 31), carcinosarcoma 16), giant cell sarcoma 14), spindle 12). Ninety-seven (40.9%) lobectomies or...
Clinically significant posthepatectomy liver failure (PHLF B+C) remains the main cause of mortality after major hepatic resection. This study aimed to establish an APRI+ALBI, aspartate aminotransferase platelet ratio (APRI) combined with albumin-bilirubin grade (ALBI), based multivariable model (MVM) predict PHLF and compare its performance indocyanine green clearance (ICG-R15 or ICG-PDR) albumin-ICG evaluation (ALICE).
Background: The premise of minimally invasive surgery (MIS) is to minimize facial and muscle injury in order enhance recovery from surgery. Robotic MIS for resection tumors solid organs gaining traction, though clear superiority this approach lacking robotic more expensive. Our philosophy robotically-assisted hepatectomy has been employ cases where location make difficult a classical laparoscopic (superior/posterior tumors), the incision an open operation dominates course recovery. Methods:...
Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes generation characterization of oncolytic chimeric orthopoxvirus for treatment pancreatic cancer. After chimerization high-throughput screening, CF33 was chosen from 100 new isolates its ability to kill cancer cells. In vitro cytotoxicity assayed six cell lines. vivo efficacy toxicity were evaluated PANC-1 MIA...
Oncolytic viruses have shown excellent safety profiles in preclinical and clinical studies; however, most cases therapeutic benefits been modest. We previously reported the generation of a chimeric poxvirus (CF33), with significantly improved oncolytic characteristics, through chimerization among different poxviruses. Here we report sequence analysis CF33 potential GFP-encoding virus (CF33-GFP) J2R deletion lung cancer models. Replication CF33-GFP resulting cytotoxicity were higher cell...
Triple-negative breast cancer is the most aggressive subtype of and difficult to treat. Breast considered be poorly immunogenic hence less responsive immunotherapies. We tested whether oncolytic poxvirus CF33-hNIS-ΔF14.5 could modulate tumor immune microenvironment make tumors checkpoint inhibitor anti-PD-L1. found that virus infection causes upregulation PD-L1 levels on triple-negative cells in vitro as well vivo mice. In a mouse model orthotopic cancer, was increase infiltration by CD8+ T...